Abstract
Dantrolene, a skeletal muscle relaxant, has been proven prophylactic and therapeutic for malignant hyperthermia (MH) in swine. This study examined the feasibility of using a dantrolene dose response as measured by indirectly evoked foretoe twitch depression as a means to safely discriminate MH susceptibility in swine. The effect of halothane on the dantrolene response was quantified. Subjects were five Poland China malignant hyperthermia susceptible (MHS) and five Hampshire malignant hyperthermia resistant (MHR) swine. Dantrolene dose response was determined twice in each anaesthetized subject, once with thiopentone and subsequently with thiopentone and halothane. Dantrolene in incremental doses, 0.15mg kg-1, was given to a cumulative dose of 2-3 mg kg-1. Under thiopentone anaesthesia, the dantrolene dose responses were similar in MHS and MHR animals. The presence of halothane augmented dantrolene twitch depression in MHS but not MHR animals when compared to their response under thiopentone. Under halothane, the MHS animals had significantly augmented dantrolene response compared to MHR pigs, but three MHS animals had developed the MH syndrome prior to receiving dantrolene. We conclude that dantrolene muscle relaxant dose response cannot be used as a diagnostic test for MHS in swine. Halothane augments dantrolene twitch depression in MHS swine.
Résumé
Le dantrolène, un relaxant du muscle squelettique, s’est avéré efficace pour la prevention et le traitement de ľhyperthermie maligne chez le pore. Les auteurs ont étudié la possibilité ďutiliser cet agent comme moyen de dépislage de la susceptibilité à ľhyperthermie maligne en mesurant la réponse en tension de I'orteil antérieur à ľadministration du dantrolène. Ľinfluence de ľhalothane sur cette réponse a également été étudiée. Cinq pores susceptibles à ľhyperthermie maligne et cinq pores non susceptibles ont été utilisés. La réponse au dantrolène a été mesurée à deux reprises chez chaque animal anesthésié, la premiére fois au thiopenthal et la seconde au thiopenthal et halothane. La dose de dantrolène était progressivement augmentée de 0.15 mgkg-1 jusqu’ à un total cumulatif de 2 à 3 mgkg-1. Sous thiopenthal, ľeffet du dantrolène ètait le meme chez les animaux susceptibles ďhyperthermie maligne que chez ceux résistant à cette pathologic Les animaux susceptibles avaient une plus forte réponse au dantrolène que les normaux lorsque ľon ajoutait ľhalothane au thiopenthal, mais trois animaux présentèrent une hyperthermic maligne avant que ľon ait eu le temps de leur administrer le dantrolène. II est conclu que la réponse à une dose de dantrolène ne peut être utilisée comme test de ľhyperthermie maligne chez le pore et que ľhalothane augmente la dépression de la contracture produite par le dantrolène.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Briti, B.A., Endrlnyi L., Peters, P.L., Kwong, F.H.F. &Kadijevic, L. Screening of malignant hyperthermia susceptible families by creatine phosphokinase measurement and other clinical investigations. Can. Anaesth. Soc. J.23: 263–284 (1976).
Zsigmond, E.K., Starkweather, W.H., Du-boff, G.S.,et al. CPK and malignant hyperthermia. Anesth. Analg. (Cleve)51: 220–225 (1972).
Aldrete, J.A., Padfield, A., Solomon, C.C. &Rubright, M. Possible predictive tests for malignant hyperthermia during anesthesia. J.A.M.A.215: 1465–1469(1971).
Zsigmond, E.K., Penner, J. &Kothary, S.P. Normal erythrocyte fragility and abnormal platelet aggregation in MH families: a pilot study. 2nd International Symposium on Malignant Hyperthermia. Ed. Aldrete, J.A., Britt, B.A. Grune and Stratton, New York, pp. 213–219(1978).
Solomons, C.C., Tan, S. &Aldrete, J.A. Platelet metabolism and malignant hyperthermia. 2nd International Symposium on Malignant Hyperthermia. Ed. Aldrete, J.A. & Britt, B.A., New York, Grune and Stratton, pp. 221–225 (1978).
Nllson, T.E., Austin, K.L. &Denborough, M.A. Screening for malignant hyperpyrexia. Br. J. Anaesth.49: 167–171(1977).
Kalow, W., Britt, B.A. &Peters, P. Rapid simplified techniques for measuring caffeine contraction for patients with malignant hyperthermia. 2nd International Symposium on Malignant Hyperthermia. Ed. Aldrete, J.A. & Britt, B.A., New York, Grune and Stratton, pp. 339–350 (1978).
Britt, B.A., Endrenyi. L, Kalow, W.,et al. The adenosine triphosphate (ATP) depletion test: comparison with the caffeine contracture test as a method of diagnosing malignant hyperthermia susceptibility. Can. Anaesth. Soc. J.23: 263–284 (1976).
Ryan, J.F.,Sneter, F.A. &Domon, J.V.In vitro measurement of calcium transfer across the sarcoplasmic reticulum membrane as a predictor of malignant hyperthermia. Abstracts of Scientific Papers. Am. Soc. Anesth., pp. 431-432(1976).
Britt, B.A., McComas, A.J., Endri-nyi., L. &Kalow, W. Motor unit counting and the caffeine contracture test in malignant hyperthermia. Anesthesiology47: 490–497(1977).
Britt, B.A., Harrison, J.E. &McNeil, K.G.In vivo neutron activation analysis for bone calcium (INAA) in malignant hyperthermia susceptible patients. Can. Anaesth. Soc. J.26: 117–124 (1979).
Harriman, D.G.F., Ellis, F.R., Franks, A.J. &Sumner, D.W. Malignant hyperthermia myopathy in man: an investigation of 75 families. 2nd International Symposium on Malignant Hyperthermia. Ed.Aldrete, J. A. &Britt, B.A., New York, Grune and Stratton, pp. 67–87 (1978).
Gronert, G.A. &Theye, R.A. Halothane- induced porcine malignant hyperthermia. Anesthesiology 44: 36–43(1976).
Harrison, G.G. Control of the malignant hyper- pyrexic syndrome in MHS swine by dantrolene sodium. Br. J. Anaesth.47: 62–65(1975).
Gronert, G.A., Milde, J.H. &Theye, R.A. Dantrolene in porcine malignant hyperthermia. Anesthesiology 44: 488–495 (1976).
Hall, G.M., Lucke, J.N. &Lister, D. Treatment of porcine malignant hyperpyrexia. Anaesthesia32: 472–474 (1977).
Harrison, G.G. The prophylaxis of malignant hyperthermia by oral dantrolene sodium in swine. Br. J. Anaesth.49: 315–317 (1977).
Kerr, D.D., Wingard, D.W. &Gatz, E.E. Prevention of porcine malignant hyperthermia by oral dantrolene. 2nd International symposium on malignant hyperthermia. New York, Grune & Stratton, Ed. Aldrete, J.A. & Britt, B.A., pp. 499–507(1978).
Nllson, T.E. Excitation-contraction coupling: a common etiologic pathway for malignant hyperthermia susceptible muscle. 2nd International Symposium on Malignant Hyperthermia. Ed. Aldrete, J.A. & Britt, B.A. New York, Grune & Stratton, pp. 23–36(1978).
Nllson, T.E. &Flewellen, E.H. Rationale for dantrolene versus procainamide for treatment of malignant hyperthermia. Anesthesiology50: 118–122(1979).
Ellis, K.O. &Carpenter, J.F. Studies on the mechanism of action of dantrolene sodium. Naunyn-Schmiedeberg’s Arch. Pharmacol.275: 83–94(1972).
Morgan, K.G. &Bryant, S.H. The mechanism of action of dantrolene sodium. J. Pharm. and Exp. Ther. 201: 138–147(1977).
Katz, R.L. &Gissen, A.J. Neuromuscular and electromyographic effects of halothane and its interaction with d-tubocurarine in man. Anesthesiology28: 564–567 (1967).
Ellis, K.O., Wessels, F.C. &Carpenter, J.F. Effects of intravenous dantrolene sodium in respiratory and cardiovascular functions. J. Pharm. Sci.65: 1359–1364(1976).
Nelson, T.E. &Denborough, M.A. Studies on normal human skeletal muscle in relation to the pathopharmacology of malignant hyperpyrexia. Clin. Exp. Pharmacol. Physiol.4: 315–322 (1977).
Ellis, F.R., Klanly, N.P. Harriman, D.G.F., Sumner, D.W., Kyei-Mensah, K., Tyrrell, J.H., Hargreavls. J.B., Parikh, R.K. &Mul-rooney, P.L. Screening for malignant hyperpyrexia. Br. Med. J. 3: 559–561 (1972).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Flewellen, E.H., Nelson, T.E. & Bee, D.E. Porcine malignant hyperthermia — failure of dantrolene dose response to diagnose susceptibility (halothane effect). Canad. Anaesth. Soc. J. 27, 16–21 (1980). https://doi.org/10.1007/BF03006842
Issue Date:
DOI: https://doi.org/10.1007/BF03006842